Barclays PLC Janux Therapeutics, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Barclays PLC holds 174,061 shares of JANX stock, worth $9.77 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

174,061

Previous 174,061 -0.0%

Holding current value

$9.77 Million

Previous $7.91 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$35.29 - $50.26 $5.11 Million - $7.28 Million	144,883 Added 496.55%	174,061 $7.91 Million
Q2 2024 Aug 14, 2024	BUY	$35.12 - $64.78 $480,371 - $886,060	13,678 Added 88.25%	29,178 $1.22 Million
Q1 2024 May 15, 2024	SELL	$7.93 - $49.75 $255,520 - $1.6 Million	-32,222 Reduced 67.52%	15,500 $584,000
Q4 2023 Feb 15, 2024	BUY	$5.85 - $11.7 $174,330 - $348,660	29,800 Added 166.28%	47,722 $511,000
Q3 2023 Nov 07, 2023	BUY	$9.56 - $14.0 $118,955 - $174,202	12,443 Added 227.1%	17,922 $181,000
Q2 2023 Aug 03, 2023	SELL	$11.08 - $15.92 $37,949 - $54,526	-3,425 Reduced 38.47%	5,479 $65,000
Q1 2023 May 04, 2023	BUY	$11.25 - $22.21 $48,330 - $95,414	4,296 Added 93.23%	8,904 $108,000
Q4 2022 Feb 13, 2023	BUY	$11.1 - $18.26 $43,068 - $70,848	3,880 Added 532.97%	4,608 $61,000
Q3 2022 Nov 03, 2022	SELL	$10.82 - $16.84 $1,428 - $2,222	-132 Reduced 15.35%	728 $10,000
Q2 2022 Aug 12, 2022	SELL	$9.52 - $15.65 $19,877 - $32,677	-2,088 Reduced 70.83%	860 $11,000
Q1 2022 May 16, 2022	BUY	$13.24 - $20.24 $39,031 - $59,667	2,948 New	2,948 $42,000

Others Institutions Holding JANX

# of Institutions

166

Shares Held

37.6M

Call Options Held

85.3K

Put Options Held

654K

View Full List

About Janux Therapeutics, Inc.

Ticker JANX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,663,000
Market Cap $2.34B
Description
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...

More about JANX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account